Nordic Life Science 1
TOP STORIES ACQU I SITIONS // AGREEMENTS // COLLA
BOR ATIONS Gunilla Osswald, CEO, BioArctic Mathias Uhlén, Chairman, ScandiBio Therapeutics MEDTECH Mölnlycke Health Care establishes first wound care manufacturing site in China The manufacturing site, spanning 10,000 m2 is exR&D 2 x Progress in Alzheimer's 1 FIRST PATIENT TREATED WITH LEQEMBI IN THE NORDICS BioArctic’s Leqembi has now been made available at a private clinic in Finland. Leqembi received EC approval in April 2025 as the first therapy that targets an underlying cause of Alzheimer’s disease (AD). It is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to AD (early AD) who are apolipoprotein E E 4 non-carriers or heterozygotes with confirmed amyloid pathology. This marks an important strategic step for BioArctic on the “It is great to see that after more than 20 years of R&D, this innovation, based on Professor Lars Lannfelt’s research at Uppsala University here in Sweden, is finally beginning to help patients close to where it all started.” GUNILLA OSSWALD, CEO, BIOARCTIC 2 pected to initiate production of Mölnlycke wound care products at the end of 2026/early 2027. company’s journey towards building Sweden’s next major pharma company, it states. “It is great to see that after more than 20 years of R&D, this innovation, based on Professor Lars Lannfelt’s research at Uppsala University here in Sweden, is finally beginning to help patients close to where it all started,” says Gunilla Osswald, CEO, BioArctic. SCANDIBIO THERAPEUTICS INITIATES PHASE 3 TRIAL The multicenter, phase 3 human clinical trial will evaluate the efficacy and safety of the company’s Combined Metabolic Activator (CMA) in patients with AD. CMA is designed to address one of the underlying causes of disease progression, mitochondrial dysfunction, by enhancing NAD+ metabolism, stimulating fatty acid oxidation, and reducing oxidative stress. It is a formulation taken orally and consists of L-serine, N-acetyl-L-cysteine (NAC), nicotinamide, and L-carnitine tartrate. The trial is taking place across nine clinical centers in Turkey and targets patients with mild, moderate, and severe symptoms. The trial, involving over 600 patients, is one of the largest clinical programs to date targeting mitochondrial dysfunction in neurodegeneration. ScandiBio expects to complete the study during the latter part of 2026. "My hope for the future is that it will be possible to improve the cognitive function of Alzheimer’s patients and thus complement the current therapies based on antibodies,” says Mathias Uhlén, Chairman, ScandiBio. NLS Ribbon-cutting NORDICLIFESCIENCE.ORG | 11 “OUR SITE IN Changshu marks another step forward in Mölnlycke’s ambition to manufacture products closer to where they are sold. It reflects our glocal approach, combining global standards with local relevance, and reinforces our commitment to sustainable growth, supply chain resilience and faster delivery of life-changing wound care solutions to caregivers and patients in China,” says Zlatko Rihter, CEO of Mölnlycke. “This investment brings us closer to our customers in China and reinforces our mission to free patients and caregivers from the burden of wounds, with locally produced, highquality solutions,” adds Jakob Sonnenberg, VP Greater China & India Wound Care at Mölnlycke. NLS PHOTO GUSTAV CEDER PHOTO MÖLNLYCKE HEALTH CARE